245 reports of this reaction
1.0% of all GLYCERIN, LIDOCAINE reports
#17 most reported adverse reaction
APPLICATION SITE ERYTHEMA is the #17 most commonly reported adverse reaction for GLYCERIN, LIDOCAINE, manufactured by Haleon US Holdings LLC. There are 245 FDA adverse event reports linking GLYCERIN, LIDOCAINE to APPLICATION SITE ERYTHEMA. This represents approximately 1.0% of all 25,225 adverse event reports for this drug.
Patients taking GLYCERIN, LIDOCAINE who experience application site erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE ERYTHEMA is a less commonly reported adverse event for GLYCERIN, LIDOCAINE, but still significant enough to appear in the safety profile.
In addition to application site erythema, the following adverse reactions have been reported for GLYCERIN, LIDOCAINE:
The following drugs have also been linked to application site erythema in FDA adverse event reports:
APPLICATION SITE ERYTHEMA has been reported as an adverse event in 245 FDA reports for GLYCERIN, LIDOCAINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE ERYTHEMA accounts for approximately 1.0% of all adverse event reports for GLYCERIN, LIDOCAINE, making it a notable side effect.
If you experience application site erythema while taking GLYCERIN, LIDOCAINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.